{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:54:07Z","timestamp":1790967247720,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40262-020-00951-6","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:02:57Z","timestamp":1603774977000},"page":"153-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-6651","authenticated-orcid":false,"given":"Jennifer N.","family":"Clements","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Gambill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"951_CR1","unstructured":"Centers for Disease Control. Diabetes Report Card 2017. 2020. https:\/\/www.cdc.gov\/diabetes\/library\/features\/diabetes-stat-report.html. Accessed 1 Jun 2020."},{"key":"951_CR2","unstructured":"International Diabetes Foundation. About Diabetes. 2020. https:\/\/www.idf.org\/aboutdiabetes\/what-is-diabetes\/facts-figures.html. Accessed 14 Jun 2020."},{"key":"951_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","volume":"54","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10\u20138.","journal-title":"Diabetologia."},{"issue":"Suppl 2","key":"951_CR4","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. Diabetes Care. 2011;34(Suppl 2):S279\u201384.","journal-title":"Diabetes Care."},{"key":"951_CR5","unstructured":"Byetta\u00ae (exenatide) [US Prescribing Information]. San Diego Amylin Pharmaceuticals; Oct 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf. Accessed 23 Oct 2020."},{"key":"951_CR6","unstructured":"Bydureon\u00ae (exenatide extended-release) [US Prescribing Information]. San Diego: Amylin Pharmaceuticals; Apr 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022200s026lbl.pdf. Accessed 23 Oct 2020."},{"key":"951_CR7","unstructured":"Victoza\u00ae (liraglutide) [US Prescribing Information]. Plainsboro: Novo Nordisk; Aug 2020. https:\/\/www.novo-pi.com\/victoza.pdf. Accessed 23 Oct 2020."},{"key":"951_CR8","unstructured":"Trulicity\u00ae (dulaglutide) [US Prescribing Information]. Indianapolis: Eli Lilly; Feb 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf. Accessed 23 Oct 2020."},{"key":"951_CR9","unstructured":"Ozempic\u00ae (semaglutide) [US Prescribing Information]. Plainsboro: Novo Nordisk; Jan 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf. Accessed 23 Oct 2020."},{"key":"951_CR10","unstructured":"Adlyxin\u00ae (lixisenatide) [US Prescribing Information]. Bridgewater: Sanofi; Jan 2019. http:\/\/products.sanofi.us\/Adlyxin\/Adlyxin.pdf. Accessed 23 Oct 2020."},{"key":"951_CR11","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142012. Diabetes Care. 2012;35(Suppl 1):S11\u2013S63. https:\/\/doi.org\/10.2337\/dc12-s011.","DOI":"10.2337\/dc12-s011"},{"key":"951_CR12","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. Section\u00a09. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Suppl 1):S98\u2013S110. https:\/\/doi.org\/10.2337\/dc20-S009.","DOI":"10.2337\/dc20-S009"},{"key":"951_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med."},{"key":"951_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med."},{"key":"951_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med."},{"key":"951_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet."},{"issue":"1","key":"951_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary. Endo Pract. 2020;26(1):107\u201339.","journal-title":"Endo Pract."},{"key":"951_CR18","unstructured":"Rybelsus\u00ae (semaglutide) [US Prescribing Information]. Bagsvaerd: Novo Nordisk; Jan 2020. https:\/\/www.novo-pi.com\/rybelsus.pdf. Accessed 23 Oct 2020."},{"issue":"12","key":"951_CR19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","volume":"57","author":"S Hall","year":"2018","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 2018;57(12):1529\u201338.","journal-title":"Clin Pharmacokinet."},{"key":"951_CR20","first-page":"A315","volume":"66","author":"TA Barkdal","year":"2017","unstructured":"Barkdal TA, Borregaard J, Donsmark M, et al. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66:A315.","journal-title":"Diabetes."},{"issue":"8","key":"951_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/17425255.2018.1488965","volume":"14","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Exp Opin Drug Metab Toxicol. 2018;14(8):869\u201377.","journal-title":"Exp Opin Drug Metab Toxicol."},{"issue":"9","key":"951_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"TA B\u00e6kdal","year":"2019","unstructured":"B\u00e6kdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193\u2013203.","journal-title":"Clin Pharmacokinet."},{"key":"951_CR23","doi-asserted-by":"crossref","unstructured":"Jordy AB, Breitschaft A, Christiansen E, et al. Oral semaglutide does not affect the bioavailability of the combined contraceptive ethynyl estradiol\/levonorgestrel. In: Paper presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD); 1\u20135 October 2018; Berlin.","DOI":"10.2337\/db18-1135-P"},{"key":"951_CR24","doi-asserted-by":"crossref","unstructured":"Hauge C, Breitschaft A, Hartoft\u2010Nielsen ML, Jensen S, B\u00e6kdal TA. A drug\u2010drug interaction trial of oral semaglutide with levothyroxine and multiple co\u2010administered tablets. In: Paper presented at the 101st Annual Meeting and Expo of the Endocrine Society (ENDO); 23\u201326 March 2019; New Orleans, LA.","DOI":"10.1210\/js.2019-SAT-140"},{"key":"951_CR25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall C, Sondergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57:1571\u201380.","journal-title":"Clin Pharmacokinet."},{"key":"951_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"TA Baekdal","year":"2018","unstructured":"Baekdal TA, Thomsen M, Kupcova V, et al. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58:1314\u201323.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"951_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","volume":"58","author":"C Granhall","year":"2019","unstructured":"Granhall C, Bonsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781\u201391.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"951_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/dom.14054","volume":"22","author":"TK Thethi","year":"2020","unstructured":"Thethi TK, Pratley R, Meier JJ. Efficacy, safety, and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263\u201377.","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"951_CR29","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosensock J, Teauchi Y, et al. PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care."},{"issue":"15","key":"951_CR30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA."},{"issue":"5","key":"951_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety or oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377\u201391.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"951_CR32","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani L, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care."},{"issue":"15","key":"951_CR33","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized control trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA."},{"issue":"7","key":"951_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10192","key":"951_CR35","first-page":"39","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Tetens Hoff S, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet Diabetes Endocrinol. 2019;394(10192):39\u201350.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"951_CR36","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care."},{"issue":"5","key":"951_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomized, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"951_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(20)30079-6","volume":"8","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2020;8(5):350\u20132.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"951_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"951_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med."},{"key":"951_CR41","unstructured":"Novo Nordisk A\/S. A research study comparing a new medicine oral semaglutide to placebo in people with type 2 diabetes (PIONEER 11). ClinicalTrials.gov identifier NCT0410954. 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04109547?term=PIONEER+11&draw=2&rank=1. Accessed 1 Jun 2020"},{"key":"951_CR42","unstructured":"Novo Nordisk A\/S. A research study comparing a new medicine oral semaglutide to sitagliptin in people with type 2 diabetes (PIONEER 12). ClinicalTrials.gov identifier NCT0401783. 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04017832?term=PIONEER%2C+oral+semaglutide&recrs=abdf&draw=2&rank=1. Accessed 1 Jun 2020"},{"key":"951_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13899","volume":"22","author":"I Avgerinos","year":"2020","unstructured":"Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22:335\u201345.","journal-title":"Diabetes Obes Metab."},{"key":"951_CR44","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1016\/j.xphs.2019.04.022","volume":"108","author":"A Abramson","year":"2019","unstructured":"Abramson A, Halperin F, Kim J, Traverso G. Quantifying the value of orally delivered biologic therapies: a cost-effectiveness analysis of oral semaglutide. J Pharm Sci. 2019;108:3138\u201345.","journal-title":"J Pharm Sci."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00951-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:22:59Z","timestamp":1635290579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00951-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00951-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"4 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funds were used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diana Isaacs has served on the speaker\u2019s bureau for Novo Nordisk. Jennifer Clements, Rachel Hartman, and Kennedy Gambill declare no potential conflicts that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}